France Diabetes Device Market Forecast Report by Types (Self-Monitoring Devices, Continuous Glucose-Monitoring Devices, Insulin Pumps, Insulin Pens), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies

France Diabetes Device Market Forecast Report by Types (Self-Monitoring Devices, Continuous Glucose-Monitoring Devices, Insulin Pumps, Insulin Pens), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies) and Company Analysis 2024-2032

France Diabetes Device Market Size

The France Diabetes Device market is expected to reach US$ 946.9 Million in 2023 to US$ 1,784.6 Billion by 2032, with a CAGR of 7.30 % from 2024 to 2032. The market for diabetes care devices in France is also being driven by factors such as the increasing incidence of diabetes and obesity, expanding awareness of diabetic care, healthcare spending, and technical improvements.

France Diabetes Device Overview

Over 3 million people in France are reported to have treated diabetes at a rate of 4.6%, and in Northern France, that number rises to 5.2%. The diabetes market is primarily driven by the need for healthcare to treat and control diabetes. Insulin pumps, continuous glucose monitoring (CGM), and self-monitoring of blood glucose (SBMG) comprise the diabetes market in France. According to a poll by the European Commission, 10% of French adults have diabetes.

But among European countries, France does not have the greatest prevalence of diabetes. At 15.4% of adult population, Germany had the highest rate of diabetes in 2022. Portugal came in second with a rate of 14.6%. However, Ireland's 4.5% diabetes rate was the lowest in all of Europe. Nevertheless, the World Health Organization (WHO) reports that almost a million French adults have a diabetes diagnosis. Furthermore, among all chronic illnesses, diabetes has the highest prevalence in France.

Of all the chronic disorders that are fully covered by France's statutory health insurance (SHI), diabetes has the highest prevalence; within the last ten years, the number of patients who are covered has doubled. One of the principal nations in the European Union is France.

The World Health Organization (WHO) estimates that one million people in France have a diabetes diagnosis. Diabetes is becoming more common in France among all age groups, which might be linked to the country's rising obesity rate as well as bad eating habits and sedentary lifestyles. In addition, it is predicted that 0.26 million people in the area have Type 1 diabetes.

Growth Drivers for the France Diabetes Device Market

France's Diabetes Population is Growing Increasing the Market for Diabetes Devices in France

Among the 59 countries that make up the IDF-EUR area is France. Furthermore, 538 million people globally and 62 million people in the Europe Region were predicted to have diabetes in 2022; by 2045, this figure is predicted to rise to 69 million. As per a report conducted by the European Commission, one in ten individuals in France have diabetes, making it the country with the greatest prevalence of chronic diabetes.

France has a high rate of diabetes, despite the fact that the regulations' goal of 80% compliance with recommended medical consultations isn't always reached. New approaches that emphasize patient and physician education and information are required to reduce the burden of complications and hospitalizations related to diabetes in order to encourage proactive therapy adjustment and diminish therapeutic inertia.

According to a 2022 article titled ""Epidemiology and Health Impact of Diabetes in France,"" after a 5-year period, patients with diabetes type-1 reported more diabetes-related difficulties than type-2 (52.2 vs. 34.7%). Additionally, across a two-year period, patients with diabetes type-1 had a higher frequency of diabetes-related admissions (29.8% vs. 16.9%) than patients with diabetes type-2.

Growing Health Concerns

The management of diabetes is becoming more widely known, which has a big impact on patient behavior and treatment decisions. individuals are increasingly inclined to look for improved diabetes management strategies as more individuals become aware of the dangers and difficulties connected to the disease. Information regarding effective monitoring and treatment choices is being disseminated through community initiatives, educational programs, and public health campaigns. This increased awareness stimulates demand for cutting-edge diabetes solutions and gadgets as well as healthy lifestyle adoption. Healthcare providers are responding to patients' pro-active caregiving with creative solutions that improve management and overall results.

France Diabetes Device Company Analysis

The major participants in the France Diabetes Device market includes BD, Medtronic, Tandem Diabetes Care, Novo Nordisk A/S, Roche, Abbott Laboratories, Eli Lilly, Ypsomed AG, Dexcom Inc.

France Diabetes Device Company News

In September 2023, According to Dexcom, those with diabetes can now access their Dexcom ONE system in France, which provides real-time continuous glucose monitoring (CGM). This development in diabetes technology accessibility is a major win for the diabetic community, as it will make this life-saving equipment available to an extra 500,000 diabetics in France.

In April 2022, the development and commercialization of an integrated automated insulin delivery (AID) system is set to alleviate the burden of diabetes treatment for individuals living in European countries, according to a partnership between CamDiab and Ypsomed. The goal of the new integrated AID system is to link the world's smallest and most accurate continuous glucose monitoring sensor, the Abbott FreeStyle Libre 3, to CamDiab's CamAPS FX mobile app. From there, the app connects to Ypsomed's mylife YpsoPump, enabling an automated and intelligent process for insulin delivery based on real-time glucose data.

Types- Industry is divided into 4 viewpoints:

1. Self-Monitoring Devices
2. Continuous Glucose-Monitoring Devices
3. Insulin Pumps
4. Insulin Pens

Distribution Channel- Industry is divided into 4 viewpoints:

1. Hospital Pharmacies
2. Retail Pharmacies
3. Diabetes Clinics/Centers
4. Online Pharmacies

All companies have been covered with 5 Viewpoints

1. Overviews
2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue

Company Analysis

1. BD
2. Medtronic
3. Tandem Diabetes Care
4. Novo Nordisk A/S
5. Roche
6. Abbott Laboratories
7. Eli Lilly
8. Ypsomed AG
9. Dexcom Inc

Key Questions Answered in Report:

1. How big is the France Diabetes Device industry?
2. What is the France Diabetes Device industry growth rate?
3. Who are the key players in France Diabetes Device industry?
4. What are the factors driving the France Diabetes Device industry?
5. Which Region held the largest market share in the France Diabetes Device industry?
6. What segments are covered in the France Diabetes Device Market report?